S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
NASDAQ:SCLX

Scilex - SCLX Competitors

$8.81
-0.07 (-0.79%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.60
$9.76
50-Day Range
$2.87
$11.32
52-Week Range
$2.87
$11.69
Volume
421,919 shs
Average Volume
467,037 shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SCLX vs. NVAX, SANA, AVXL, RGNX, VALN, AGEN, ITOS, EXAI, CHRS, and ALEC

Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Novavax (NVAX), Sana Biotechnology (SANA), Anavex Life Sciences (AVXL), REGENXBIO (RGNX), Valneva (VALN), Agenus (AGEN), iTeos Therapeutics (ITOS), Exscientia (EXAI), Coherus BioSciences (CHRS), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.

Scilex vs.

Novavax (NASDAQ:NVAX) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.

Novavax has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Scilex has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500.

Scilex has a net margin of 0.00% compared to Novavax's net margin of -71.59%. Novavax's return on equity of 0.00% beat Scilex's return on equity.

Company Net Margins Return on Equity Return on Assets
Novavax -71.59% N/A -51.33%
Scilex N/A -16.72% 1.34%

Scilex has lower revenue, but higher earnings than Novavax.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$1.15 billion0.77-$1.74 billion-$17.30-0.65
ScilexN/AN/A$780 thousandN/AN/A

In the previous week, Novavax had 5 more articles in the media than Scilex. MarketBeat recorded 12 mentions for Novavax and 7 mentions for Scilex. Novavax's average media sentiment score of 0.44 beat Scilex's score of 0.35 indicating that Novavax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novavax
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Scilex
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Novavax received 837 more outperform votes than Scilex when rated by MarketBeat users.

CompanyUnderperformOutperform
NovavaxOutperform Votes
837
75.34%
Underperform Votes
274
24.66%
ScilexN/AN/A

Novavax presently has a consensus target price of $92.50, suggesting a potential upside of 719.31%. Given Novavax's higher probable upside, equities analysts clearly believe Novavax is more favorable than Scilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
2 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.29
Scilex
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

45.7% of Novavax shares are held by institutional investors. Comparatively, 72.7% of Scilex shares are held by institutional investors. 2.1% of Novavax shares are held by company insiders. Comparatively, 20.0% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Novavax beats Scilex on 8 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLX vs. The Competition

MetricScilexBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.25B$2.83B$4.51B$5.76B
Dividend YieldN/A2.00%2.34%4.04%
P/E RatioN/A7.95154.2213.23
Price / SalesN/A152.103,580.2678.26
Price / Cash264.1029.5623.27108.77
Price / Book-29.372.786.335.85
Net Income$780,000.00$97.07M$164.78M$242.13M
7 Day Performance-22.17%3.46%5.66%5.11%
1 Month Performance206.97%26.14%30.96%25.17%
1 Year PerformanceN/A-17.51%-1.22%-7.03%

Scilex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVAX
Novavax
1.922 of 5 stars
$11.55
-3.1%
$104.63
+805.8%
-84.5%$906.72M$1.15B-0.671,541
SANA
Sana Biotechnology
1.6543 of 5 stars
$4.71
+2.4%
$10.50
+122.9%
-39.5%$898.32MN/A-2.93383Analyst Report
News Coverage
AVXL
Anavex Life Sciences
1.8222 of 5 stars
$10.72
+2.4%
$45.25
+322.1%
-8.7%$835.75MN/A-17.2925Negative News
RGNX
REGENXBIO
2.3616 of 5 stars
$23.54
+3.8%
$41.43
+76.0%
-7.0%$1.02B$470.35M15.19372Analyst Revision
News Coverage
VALN
Valneva
1.7228 of 5 stars
$14.98
-1.8%
$25.00
+66.9%
-56.7%$1.04B$411.85M0.00762Gap Up
AGEN
Agenus
2.1071 of 5 stars
$2.59
+1.6%
$8.83
+240.7%
+5.6%$789.46M$295.67M-3.20441
ITOS
iTeos Therapeutics
1.6987 of 5 stars
$22.19
+5.5%
$34.00
+53.2%
-38.2%$789.41M$344.77M3.2394Short Interest ↑
Positive News
EXAI
Exscientia
1.943 of 5 stars
$6.06
+5.0%
$15.67
+158.5%
-57.7%$744.64M$37M-3.05285News Coverage
Positive News
CHRS
Coherus BioSciences
2.0493 of 5 stars
$9.12
-0.7%
$16.50
+80.9%
-27.3%$709.34M$326.55M-2.53332News Coverage
ALEC
Alector
2.0458 of 5 stars
$8.57
+1.5%
$17.00
+98.4%
-35.0%$708.76M$207.09M-5.16208Analyst Report
This page (NASDAQ:SCLX) was last updated on 1/28/2023 by MarketBeat.com Staff